早期卵巢癌前哨淋巴结活检:前瞻性多中心研究(SELLY)的初步结果
SELLY试验为前瞻性II期单臂研究,评估前哨淋巴结检测预测早期上皮性卵巢癌淋巴结状态的可行性、安全性和准确性。前31例患者中检出率67.7%,立即分期组检出率88.9%显著高于延迟分期组41.7%(P=.003)。4例淋巴结阳性患者中前哨淋巴结均阳性(灵敏度100%,假阴性率0%)。
要点
- 前哨淋巴结总检出率为67.7%,立即分期组88.9%显著高于延迟分期组41.7%(P=.003)
- 4例淋巴结阳性患者中前哨淋巴结均阳性,灵敏度100%,假阴性率0%,阴性预测值100%
- 发生1例(3.2%)术中及2例(6.5%)术后I级并发症
核心结论
- 早期上皮性卵巢癌患者接受延迟分期手术时前哨淋巴结检出率低。
- 前哨淋巴结操作可行,有潜力提供可靠且有用的淋巴结状态信息,并可能使大多数患者避免系统性淋巴结清扫。
研究设计与样本
- SELLY试验为前瞻性、II期、单臂研究,纳入拟行立即或延迟微创全面分期的推测I-II期上皮性卵巢癌患者。
- 卵巢门注射2 mL浓度为1.25 mg/mL的吲哚菁绿溶液,随后探查并切除前哨淋巴结,之后完成系统性盆腔及腹主动脉旁淋巴结清扫。
- 假设前哨淋巴结组织学预测阳性的灵敏度为98.5%、病理淋巴结患病率为14.2%、估计精度d=5%、I型错误α=0.05,需要160例患者检验总体假设;本文报告首批入组的31例患者初步结果。
主要发现
- 31例患者中21例检出前哨淋巴结,检出率为67.7%。
- 立即分期组检出率为88.9%,延迟分期组为41.7%,立即分期组显著高于延迟分期组(P=.003)。
- 4例患者淋巴结阳性,所有淋巴播散患者均检出阳性前哨淋巴结(灵敏度100%,假阴性率0%,阴性预测值100%)。
- 发生1例(3.2%)术中及2例(6.5%)术后I级并发症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本文报告的是首批31例患者的初步结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systematic paraaortic and bilateral pelvic lymphadenectomy is the standard of a comprehensive surgical staging in presumed early epithelial ovarian cancer, but no prospective randomized evidence suggests a possible therapeutic value. Moreover, this procedure is associated with potential severe morbidity. The Sentinel Lymph Nodes in Early-Stage Ovarian Cancer trial is a prospective study designed to test whether sentinel node detection can accurately predict nodal status in a cohort of women with early epithelial ovarian cancer. OBJECTIVES: We here present the results of the first part of the Sentinel Lymph Nodes in Early-Stage Ovarian Cancer trial, regarding the feasibility of the sentinel lymph node technique and the preliminary findings regarding its safety and accuracy. STUDY DESIGN: The Sentinel Lymph Nodes in Early-Stage Ovarian Cancer trial is a prospective, phase II, single-arm study included patients with presumed stages I-II epithelial ovarian cancer planned for immediate or delayed minimally invasive comprehensive staging. The ovarian pedicle is injected with 2 mL of a 1.25 mg/mL indocyanine green solution. The pelvic and lumboaortic retroperitoneum is then accessed and inspected to identify and remove sentinel nodes. After sentinel node procedure, staging is completed including systematic pelvic and paraaortic lymphadenectomy. Assuming a sensitivity of 98.5% in predicting positive sentinel lymph nodes at histology, a pathological lymph node prevalence of 14.2%, a precision of estimate (ie, the maximum marginal error) d = 5%, a type I error α = 0.05, a sample size of 160 patients is needed to test the general hypothesis. Here we present the preliminary results on the first 31 patients enrolled. RESULTS: Thirty-one patients were included. Sentinel node was identified in 21 patients (detection rate, 67.7%). The detection rate was significantly higher in women undergoing immediate vs delayed staging (88.9% vs 41.7%, P = .003). Four patients had positive nodes. In all the patients with lymphatic dissemination, a positive sentinel node was identified (sensitivity, 100%; false-negative rate, 0%; negative predictive value, 100%). One (3.2%) intra- and 2 (6.5%) postoperative grade I complications occurred. CONCLUSION: Our data show that the detection of sentinel node in early epithelial ovarian cancer is low when patients are submitted to delayed-staging surgery. However, sentinel node procedure is feasible and has the potential to provide reliable and useful information on nodal status and may allow the avoidance of systematic lymphadenectomy in the majority of patients.
引用
- Uccella S, Nero C, Vizza E, et al. Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY). Am J Obstet Gynecol. 2019. PMID: 31082385. doi:10.1016/j.ajog.2019.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。